Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Audentes Therapeutics Inc (BOLD)

Audentes Therapeutics Inc (BOLD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,715,848
  • Shares Outstanding, K 45,783
  • Annual Sales, $ 0 K
  • Annual Income, $ -128,820 K
  • 60-Month Beta 1.77
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -1.01
  • Number of Estimates 8
  • High Estimate -0.89
  • Low Estimate -1.07
  • Prior Year -0.84
  • Growth Rate Est. (year over year) -20.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.41 +134.20%
on 11/18/19
59.51 unch
on 12/10/19
+30.94 (+108.30%)
since 11/08/19
3-Month
25.41 +134.20%
on 11/18/19
59.51 unch
on 12/10/19
+28.43 (+91.47%)
since 09/10/19
52-Week
17.95 +231.53%
on 12/26/18
59.51 unch
on 12/10/19
+36.19 (+155.19%)
since 12/10/18

Most Recent Stories

More News
BOLD, MDCO, AYR, and PEGI SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts

Rigrodsky & Long, P.A. announces that it is investigating:

BOLD : 59.51 (+0.32%)
MDCO : 84.22 (+0.08%)
PEGI : 27.22 (-0.04%)
AYR : 32.17 (+0.22%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - INST, AKS, BOLD, SORL

Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

INST : 48.51 (-0.80%)
AKS : 3.41 (+2.71%)
BOLD : 59.51 (+0.32%)
SORL : 4.41 (+0.23%)
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Audentes Therapeutics, Inc. - BOLD

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Audentes Therapeutics,...

ALPMF : 17.0500 (-2.01%)
BOLD : 59.51 (+0.32%)
4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal

Gene therapy continues to draw attention with the recent spate of deals and acquisitions. We list four stocks with promising candidates in their pipelines that make attractive acquisition targets.

RHHBY : 38.4000 (+0.01%)
BMY : 62.09 (+1.32%)
QURE : 64.99 (+3.16%)
SRPT : 106.17 (+0.40%)
SGMO : 9.06 (-12.17%)
BMRN : 79.43 (+0.67%)
BOLD : 59.51 (+0.32%)
Company News for Dec 4, 2019

Companies In The News Are: UNH,PEP,CLF,AKS,BOLD.

PEP : 136.27 (-0.65%)
UNH : 279.52 (+0.71%)
CLF : 8.55 (+0.47%)
AKS : 3.41 (+2.71%)
BOLD : 59.51 (+0.32%)
Biotechs Move Forward Developing Latest Targeted Therapies for Acute Myeloid Leukemia

So it is not surprising that there is a lot of money and research resources being devoted to find new therapies for Acute Myeloid Leukemia (AML), many of which are in the targeted drugs arena. AML is the...

MBRX : 1.02 (-1.92%)
BOLD : 59.51 (+0.32%)
OTLK : 1.14 (-1.72%)
AXSM : 48.75 (+8.02%)
QURE : 64.99 (+3.16%)
SHAREHOLDER ALERT: WeissLaw LLP Investigates Audentes Therapeutics, Inc.

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Audentes Therapeutics, Inc. ("Audentes" or the "Company") (NASDAQ: BOLD) in connection...

ALPMF : 17.0500 (-2.01%)
BOLD : 59.51 (+0.32%)
ALPMY : 17.2600 (+0.20%)
Cleveland-Cliffs, CBL tumble while Lands’ End, ViewRay gain

NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:

BOLD : 59.51 (+0.32%)
MDT : 111.04 (-0.08%)
CDNS : 65.85 (-0.27%)
CBL : 1.05 (-5.41%)
AUDENTES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BOLD and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder law firm, has launched an investigation into whether the board members of Audentes Therapeutics, Inc. (NASDAQ: BOLD) breached their fiduciary...

ALPMF : 17.0500 (-2.01%)
BOLD : 59.51 (+0.32%)
Audentes Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Audentes Therapeutics, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm - BOLD

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Audentes Therapeutics, Inc. (NASDAQ: BOLD) to Astellas Pharma Inc. ("Astellas") for $60.00 per share is fair to...

ALPMF : 17.0500 (-2.01%)
BOLD : 59.51 (+0.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade BOLD with:

Business Summary

Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company's product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for...

See More

Key Turning Points

2nd Resistance Point 59.67
1st Resistance Point 59.59
Last Price 59.51
1st Support Level 59.35
2nd Support Level 59.19

See More

52-Week High 59.51
Last Price 59.51
Fibonacci 61.8% 43.63
Fibonacci 50% 38.73
Fibonacci 38.2% 33.83
52-Week Low 17.95

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar